The decision, released March 16 by Judge Sarah Evans Barker of U.S. District Court for the Southern District of Indiana, states that HHS messaging around the final rule was “ambiguous, confusing, duplicitous and misleading.”
The judge added that because HHS issued the final rule without additional notice or a comment period, it violated Eli Lilly’s rights. The drugmaker sued HHS over the final rule.
The blocked rule created a panel to settle disputes between hospitals and drugmakers on issues related to the 340B drug discount program. Shortly after the rule was released, HHS also released an advisory opinion stating that 340B drug discounts apply to community pharmacies contracted to dispense drugs for hospitals participating in the 340B program.
Read the full decision here.
More articles on pharmacy:
AbbVie reportedly in talks to sell $5B women’s health portfolio
NYC pharmacist charged in $4M kickback, fraud scheme
94% of older Americans prescribed a drug that increases their risk of falling, study shows
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.